

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: D. Thibeault et al) Confirm. No.: 7451
Serial No.: 10/650,585) Art Unit: 1648
Filed: August 28, 2003) Examiner: Mary Mosher
For: Purified Active HCV NS2/3 Protease
Docket No.: 13/082-1-D1

Electronically Filed Via EFS-Web
Commissioner for Patents
Alexandria, VA 22313-1450

REQUEST UNDER RULE 48(b) CORRECTING INVENTORSHIP

Sir:

Please delete the inventors identified below from the above-identified application. The inventors' invention is no longer being claimed in the application. Applicants note that the fee required under 37 CFR 1.17(i) in connection with this petition is \$130.00 and such fee is paid during electronic filing via the Revenue Accounting and Management System. Furthermore, if it is determined that any additional fees under 37 C.F.R. §§ 1.16 or 1.17 are due in connection with this Petition, authorization to charge such fees to Deposit Account No. 02-2955 is provided during electronic filing via the Revenue Accounting and Management System.

Roger Maurice, Laval, Canada
Diane Thibeault, Laval, Canada
Arnim Pause, Laval, Canada

Respectfully submitted,

/Paula K. Wittmayer/
Paula K. Wittmayer, Reg. No. 53,785
Attorney for Applicant(s)

Patent Department
Boehringer Ingelheim Corp.
900 Ridgebury Road
P.O. Box 368
Ridgefield, CT 06877
Tel.: (203) 791-6692
Dated: November 28, 2006